QuellTX
Sophie Brayne has a diverse work experience in business development and consulting roles in the biotech and pharmaceutical industries. Sophie is currently the Director of Business Development at Quell Therapeutics, where they are responsible for implementing academic/industry collaborations and strategic partnerships. Prior to this role, they served as the Associate Director of Business Development at Quell, where they contributed to the company's business operations and strategy development.
Before joining Quell Therapeutics, Sophie worked as a Business Development Manager at Cell Medica, focusing on in-licensing and out-licensing efforts for the company's cancer immunotherapy platform. Sophie also played a key role in conducting competitive intelligence monitoring and supporting alliance negotiations.
Prior to their roles in the biotech industry, Sophie worked at IP Pragmatics Ltd as a Consultant and later as a Business Development Manager. Sophie also gained experience as an Intellectual Property Intern at Bird & Bird LLP and completed a Marketing Strategic Initiatives Internship at Pfizer.
Sophie started their career as a Science Policy Adviser Intern at the Society of Biology. Overall, they possess a strong background in business development, strategic partnerships, and consulting in the biotech and pharmaceutical industries.
Sophie Brayne completed their Master of Business Administration (MBA) degree with a focus on Innovation & Entrepreneurship at Imperial College London from 2017 to 2019. Prior to that, they pursued a Bachelor's degree in Biological Sciences with a specialization in Pharmacology at The University of Edinburgh from 2007 to 2011. Additionally, Sophie also obtained another Master of Business Administration (MBA) degree at Imperial College Business School, although the specific years of study and field of study for this degree are not provided.
QuellTX
4 followers
Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions.Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cellengineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.